trending Market Intelligence /marketintelligence/en/news-insights/trending/ulTvrCfPOGF9FHiNPGY1Jg2 content esgSubNav
In This List

Lilly's Taltz performs better than J&J's Tremfya in head-to-head study

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Lilly's Taltz performs better than J&J's Tremfya in head-to-head study

Eli Lilly and Co.'s Taltz performed better than Janssen Biotech Inc.'s Tremfya in clearing the skin of patients with moderate to severe plaque psoriasis during a head-to-head clinical trial.

Psoriasis is an inflammatory autoimmune condition characterized by patches of abnormal skin on the body.

The phase 4 trial called IXORA-R met its primary goal, with a larger proportion of patients using Taltz seeing completely clear skin after 12 weeks compared to those using Tremfya.

The U.S. Food and Drug Administration has already approved Lilly's Taltz injection to treat adults with active psoriatic arthritis as well as moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The drug in a phase 3b trial also reduced sexual difficulties caused by genital psoriasis, prompting a label update approval from the FDA.

Janssen Biotech is a unit of Johnson & Johnson.